First Batch Of DRDO’s Anti-COVID Drug 2-DG Launched


New Delhi: The first batch of 10,000 doses of 2DG medicine for treating COVID-19 patients was launched today. Defence minister Rajnath Singh and health minister Dr Harsh Vardhan released the first batch of the drug, marking a landmark in India’s fight against the Covid-19 pandemic.

Developed by the DRDO’s Institute of Nuclear Medicine and Allied Sciences (INMAS), in collaboration with Dr Reddy’s Laboratories in Hyderabad, the Deoxy-D-Glucose (2-DG) drug is an anti-Covid therapeutic application.

It helps in faster recovery of the hospitalised patients and reduces oxygen dependence.

The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production.

The Drugs Controller General of India (DCGI) has approved the oral drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients, the defence ministry said earlier this month.

Comments are closed.